EVGN Evogene Ltd.
Listings ·
Nasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million.
Evogene's board backs its own seven-person slate over a rival four-person slate at a September 4 meeting, and asks for 120,000,000 more authorized shares and a reverse split of 1-for-2 to 1-for-15. Year-end cash fell to $13.0 million in 2025.
Evogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.9 million | $5.6 million |
| Research and development | $8.0 million | $12.5 million |
| Net income (loss) | -$7.8 million | -$18.1 million |
| Cash from operations | -$13.5 million | -$19.7 million |
| Cash and equivalents | $13.0 million | $15.3 million |
Our latest story on this, dated Sep 30, 2026: "Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027". The story links the filing or release it is based on. Read the story.
Evogene Ltd. trades under the ticker EVGN on NASDAQ.
Evogene Ltd. is listed on NASDAQ. Our directory also records these other listings: TASE:EVGN.
The SEC Central Index Key (CIK) for Evogene Ltd. is 1574565. Its filings are on SEC EDGAR.
8,718,193 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26.
Our directory records Evogene Ltd. under Israel.
Our directory classifies Evogene Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Evogene Ltd. is IL0011050551.
aibio.space lists Evogene Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
$3.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Evogene Ltd. reported a net loss of $7.8 million for the fiscal year ended Dec 31, 2025, and used $13.5 million of cash in operations, per its annual report to the SEC.
$8.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$13.0 million in cash at Dec 31, 2025, per its 20-F.
Our latest story on Evogene, dated Sep 30, 2026: "Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027". Nasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million. Source.
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio